SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
MAIA Biotechnology, Inc. (MAIA) has a negative trailing P/E of -1.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 0.5 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -59.10%, forward earnings yield 188.68%.
Criteria proven by this page:
- VALUE (0/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -1.7); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -59.10%).
- Forward P/E 0.5 — analysts expect a return to profitability with estimated EPS of $2.70 for FY2027.
- Trailing Earnings Yield -59.10% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 188.68% as earnings recover.
Overall SharesGrow Score: 33/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — MAIA
Valuation Multiples
P/E (TTM)-1.7
Forward P/E0.5
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.02
P/S Ratio0.00
EV/EBITDA596.0
Per Share Data
EPS (TTM)$-0.70
Forward EPS (Est.)$2.70
Book Value / Share$73.98
Revenue / Share$0.00
FCF / Share$-586.78
Yields & Fair Value
Earnings Yield-59.10%
Forward Earnings Yield188.68%
Dividend Yield0.00%
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2019 |
-7.3 |
0.00 |
-274.41 |
0.00 |
- |
| 2020 |
-7.1 |
-4.36 |
-14.22 |
0.00 |
- |
| 2021 |
-3.8 |
-0.04 |
5.17 |
0.00 |
- |
| 2022 |
-2.1 |
-0.05 |
3.83 |
0.00 |
- |
| 2023 |
-0.8 |
0.06 |
32.49 |
0.00 |
- |
| 2024 |
-1.9 |
0.06 |
12.09 |
0.00 |
- |
| 2025 |
-2.2 |
0.07 |
20.68 |
0.00 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$-0.61 |
$0.00 |
$-6.49M |
- |
| 2020 |
$-0.62 |
$0.00 |
$-6.64M |
- |
| 2021 |
$-1.18 |
$0.00 |
$-12.5M |
- |
| 2022 |
$-1.70 |
$0.00 |
$-15.81M |
- |
| 2023 |
$-1.49 |
$0.00 |
$-19.77M |
- |
| 2024 |
$-1.05 |
$0.00 |
$-23.26M |
- |
| 2025 |
$-0.70 |
$0.00 |
$-22.4M |
- |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-0.69 |
$-0.69 – $-0.69 |
$64.97M |
$64.97M – $64.97M |
1 |
| 2027 |
$2.70 |
$2.70 – $2.70 |
$66.27M |
$66.27M – $66.27M |
1 |
| 2028 |
$0.00 |
$0.00 – $0.00 |
$396.55M |
$396.55M – $396.55M |
0 |
